英国顶尖资产管理机构安石集团（Ashmore）到访苏美达资本
点击上方"苏美达资本"，精彩资讯一站式送出！
苏美达资本简讯
2016年11月22日, 安石投资集团有限公司（Ashmore Group Plc）健康医疗投资总监Ahsan Ali 先生, 机构合作总监Joe Suddaby 先生, Leong Mei Yin 女士和英国驻上海总领事馆江苏区域事务高级官员鲁健女士一行到访苏美达资本, 苏美达资本团队及苏美达集团相关部门人员参加了商谈。
会上Ahsan Ali 先生对安石集团的基本情况做了介绍，特别是其在中国的发展愿景和医疗健康板块的规划做了详细阐述 。Ahsan Ali 先生认为，由于老龄化人口激增、城市化进程不断加快，以及日益庞大的中产阶级等因素，中国未来的医疗健康产业潜力巨大，中国医疗健康花销预计以平均每年11.8%的速度在增长，到2018年将达到8920亿美元，此时进入中国投资相关产业将是非常好的机遇。安石集团拥有世界领先的临床合作伙伴，将把英国最具认知度的医疗健康品牌带入中国，未来将打造包括中国在内的新兴市场国家的一系列连锁医疗健康项目，形成全球性的资源优势和资产平台。苏美达资本对此表示赞同，苏美达资本有别于一般的财务投资者，借助四大股东及自身精干团队的优势力量，具备深厚的产业资源和遍布全球的网络平台，在医疗健康领域也将大有作为。双方均表示，苏美达资本和安石集团有着相近的投资诉求和经营理念，未来双方可以进行更加深入的合作，形成稳定的合作伙伴关系，强强联合，优势互补，开展多样化的投资策略，围绕运营改进措施、兼并收购以及其他新的发展方向共同商讨出最佳实施方案，携手创造价值。
背景介绍：
安石集团成立于1992年，是一家全球领先、精于新兴市场投资的资产管理机构，为伦敦富时指数（FTSE）100成员企业。公司总部设于伦敦，目前公司全球员工267人，投资委员会成员平均业界年资达24年，分公司遍及中国、哥伦比亚、印度、印度尼西亚、日本、沙特阿拉伯、新加坡、土耳其、阿拉伯联合大公国、英语与美国。截至2016年9月30日，安石集团管理的集合基金、独立基金和结构性产品等共计达546亿美元。2009年，中国外汇管理局批准安石集团2亿美元合格境外机构投资者（QFII）投资额度。2014年1月，安石集团成为香港以外首家宣布获得直接投资中国3.4万亿美元股市以及4.7万亿美元债市牌照的海外公司。
UK's Top Investment Management Company Ashmore Group Plc Visits Sumec Capital
On Nov 22, 2016, Ashmore Group Plc, a top Investment Management company in UK, visited Sumec Capital in Nanjing. Mr. Ahsan Ali, Mr. Joe Suddaby and Mrs. Leong Mei Yin from Ashmore Group, accompanied by Mrs. Jane Lu from the British Consulate in Shanghai, were warmly received by the Sumec Capital team and related departments of Sumec Group.
Mr. Ahsan Ali, investment director of Ashmore Group, first made a general introduction of Ashmore Group, especially its healthcare development plan in China. Mr. Ali said that, due to factors including ageing population, growing urbanization and increasing middle class, there would be a huge need for healthcare facilities and services in China. Current healthcare spending is expected to increase at an average rate of 11.8% yoy and will reach US$892 billion by 2018, which presents a great opportunity for investors to invest in related industries in China. Sumec Capital team agreed with Mr. Ali, Sumec Capital is an industrial investor instead of a financial investor, and endeavors to invest in healthcare industries supported by its shareholders’ dominant industry positions and extensive network of global and local resources. Based on the similar investment philosophies, both parties agreed to become partners and explore various cooperation strategies to create mutual value.
Ashmore Group plc, a FTSE-250 company, was established in 1992 (former ANZ Emerging Markets Fund Management Ltd) by a team of investment professionals who have been working in the Emerging Markets since the mid 1980s. Headquartered in London, it has 267 employees globally and its Investment Committee members have an average industry experience of 24 years. Ashmore Group has offices in China, Turkey, UAE, UK, Colombia, India, Indonesia, Japan, USA, Saudi Arabia and Singapore. In 2014, Ashmore became the first investment management company outside Greater China to be awarded an RMB Qualified Foreign Institutional Investor (’RQFII’) licence by the China Securities Regulatory Commission.